REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai > Cyclopeptides > 25 Or More Peptide Repeating Units In Known Peptide Chain Structure 25 Or More Peptide Repeating Units In Known Peptide Chain Structure25 Or More Peptide Repeating Units In Known Peptide Chain Structure patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.03/01/07 - 20070049532 - Modified peptides as therapeutic agents The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by selecting a peptide that modulates the activity of a protein of interest and preparing a pharmacologic agent having ... 03/01/07 - 20070049531 - Glp-1 agonist and cardiovascular complations Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist. ... 03/01/07 - 20070049530 - Cytokine receptor zcytor17 multimers Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and ... 03/01/07 - 20070049529 - Cytokine zalpha11 ligand Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller ... 03/01/07 - 20070049528 - Nucleic acid encoding cytokine receptor zcytor17 Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can ... 03/01/07 - 20070049527 - Nucleic acid encoding cytokine receptor zcytor17 Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can ... 03/01/07 - 20070049526 - Uses of human zven proteins and polynucleotides The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides. ... 03/01/07 - 20070049525 - Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation The present invention relates ZcytoR21 antagonists, such as soluble receptors and anti-ZcytoR21 antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. ZcytoR21 is a receptor for IL-17C. The present invention includes ... 03/01/07 - 20070049524 - Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation The present invention relates ZcytoR21 antagonists, such as soluble receptors and anti-ZcytoR21 antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. ZcytoR21 is a receptor for IL-17C. The present invention includes ... 03/01/07 - 20070049523 - Liquid composition of modified factor vii polypeptides The invention provides a liquid, aqueous composition, comprising (i) a modified factor VII polypeptide; (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 8.0; (iii) an antioxidant; and (iv) an agent selected from the list of: a calcium salt, a magnesium salt, or ... 03/01/07 - 20070049522 - Kallikrein-inhibitor therapies Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient. ... 03/01/07 - 20070049521 - Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof A method of using an osteocrin (Ostn) or a NPR-C specific Ostn peptide derivative for increasing osteogenesis in a mammal comprising administering a therapeutically effective amount of said Ostn or NPR-C specific Ostn peptide derivative to the mammal. ... 02/22/07 - 20070042961 - Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Three examples of such recombinant APC mutants are KKK191-193AAA-APC, RR229/230AA-APC, and RR229/230AA plus KKK191-193AAA-APC. ... 02/22/07 - 20070042960 - Methods of using zven proteins The present invention provides novel uses two members of a new family of human proteins, designated as “Zven,” as agents that stimulate gastrointestinal contractility, gastric emptying, intestinal transit, and treating gastroparesis The Zven1 gene, which resides in human chromosome 3p21.1-3p14.3, is expressed in testicular tissue and peripheral blood lymphocytes. The ... 02/22/07 - 20070042959 - Thrombin-inhibiting peptides Peptides of Formula I are useful for therapeutic purposes, among others. ... 02/22/07 - 20070042958 - Lefty, lefty derivatives and uses thereof The disclosure relates to Lefty derivatives and the uses of Lefty polypeptides as antagonists of the function of certain ligands such as Nodal, GDF-8 (Myostatin), and GDF-11. These derivatives may be fused to other functional heterologous proteins such as IgG, especially the Fc portion of IgG. According to the disclosure, ... 02/22/07 - 20070042957 - Type v phosphodiesterase inhibitors and natriuretic polypeptides This document provides methods and materials related to PDE V inhibitors, natriuretic polypeptides, and combinations thereof. For example, compositions containing one or more PDE V inhibitors in combination with one or more natriuretic polypeptides are provided herein. In addition, methods for using PDE V inhibitors, natriuretic polypeptides, and combinations thereof ... 02/22/07 - 20070042956 - Novel glp-1 compounds Novel GLP-1 compounds and their therapeutic use. ... 02/22/07 - 20070042955 - Abuse-resistant amphetamine prodrugs The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, ... 02/22/07 - 20070042954 - Compositions and methods related to soluble g-protein coupled receptors (sgpcrs) The present invention is directed to compositions and methods related to soluble G-protein coupled receptors (sGPCR). In ceratin aspects the invention includes compositions and methods related to a soluble corticotropin releasing factor receptor related protein, sCRFR2, as well as its effects on CRFR signaling and interaction between CRF family ligand ... 02/22/07 - 20070042953 - Antiepileptogenic complex of albumin with docosahexaenoate The infusion of an albumin-docosahexaenoic acid (DHA) complex was shown to inhibit the progression of kindling epileptogenesis. This was shown in mice using kindling as the experimental epilepsy model. The DHA-albumin complex was shown to affect the activity of the brain when administered intraperitoneally. This therapy could also be administered ... 02/22/07 - 20070042952 - Analogues of glp-1 Disclosed are peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, methods of using such analogues to treat mammals and pharmaceutical compositions useful therefor comprising said analogues. ... 02/22/07 - 20070042951 - Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides Disclosed herein are dosage forms comprising an alpha-2-adrenergic agonist and a trefoil factor family peptide. Related to these dosage forms are methods of treating glaucoma or reducing intraocular pressure and methods of treating gastrointestinal disorders. ... 02/22/07 - 20070042950 - Antagonistic analogs of gh rh (2003) There is provided a novel series of synthetic antagonistic analogs of hGH-RH(1-29)NH2. These analogs inhibit the activity of endogenous hGH-RH on the pituitary GH-RH receptors, and therefore prevent the release of growth hormone. The analogs also inhibit the proliferation of human cancers through a direct effect on the cancer cells. ... 02/22/07 - 20070042949 - Pharmaceutical compositions comprising an epitope of platelet gpiiia protein The present invention relates to a pharmaceutical composition for the prevention or management of a condition caused by exposure to an antithetical allele of a platelet by tolerisation, the composition comprising an immunologically effective platelet protein or peptide fragment thereof. ... 02/22/07 - 20070042948 - Vav inhibition in graft rejection The present invention provides a method for preventing or treating acute or chronic graft rejection in a recipient of cell, tissue or organ allo- or xenotransplant, inflammatory or autoimmune diseases or malignant proliferative disease, comprising the use of an inhibitor of Vav. Further provided are Vav inhibitors, uses, pharmaceutical compositions ... 02/22/07 - 20070042947 - Agents for preventing and/or treating uppper digestive tract disorders A compound or its salts that inhibit the activity of the polypeptide or receptor of the present invention and the antibody of the present invention as well as the antisense DNA of the present invention are useful as, e.g., gastric acid secretion inhibitors, mucosa protectants, mineral absorption promoters, etc., which ... 02/22/07 - 20070042946 - Peptide inhibitors of thrombin as potent anticoagulants The tetrapeptide Phe-Asn-Pro-Arg is a structurally-optimized sequence for binding to the active site of thrombin. By conjugating this tetrapeptide or variants thereof to a C-terminal fragment of hirudin, we were able to generate a series of new multivalent inhibitors of thrombin containing only genetically encodable natural amino acids. We found ... 02/22/07 - 20070042945 - Nouvelles compositions et methods de traitement du psoriasis The present invention relates to compositions and methods useful for the diagnosis and treatment of psoriasis. ... 02/22/07 - 20070042944 - Processes for the preparation of fibrinogen The present invention relates to processes for the purification of fibrinogen, and to readily solubilised fibrinogen preparations. ... 02/15/07 - 20070037750 - Methods for glucagon suppression using modified exendins Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject are provided. These methods are are useful ... 02/15/07 - 20070037749 - Therapeutic fibrin-derived peptides and uses thereof The invention relates to peptides having the general formula (I), or a salt or amide thereof, wherein R1 and R2 are either the same or different, wherein R1 and R2 are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from ... 02/15/07 - 20070037748 - Methods of treating diseases with a vegf antagonist A method of reducing or preventing hypertension associated with administration of a vascular endothelial growth factor (VEGF) antagonist in a human subjects suffering from a disease or condition treatable with a VEGF antagonist in which is it desirable to reduce or prevent hypertension. The method is particularly useful for treatment ... 02/15/07 - 20070037747 - Exendin 4 polypeptide fragment The present invention relates to an Exendin 4 polypeptide fragment, which has hypoglycemic activity, and can be used for the treatment of type II diabetes mellitus. The polypeptide sequence described herein is HGEGTX1TSDLSKQX2EEEAVX3LFIEWLKNGX4PX5, where X1 represents Phe or Tyr, X2 represents Met, Ile or Leu, X3 represents Lys, X4 represents ... 02/15/07 - 20070037746 - Novel compounds The present invention relates to novel coagulation factor FVIIa polypeptides. ... 02/15/07 - 20070037745 - Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer A novel gene (designated 213P1F11) and its encoded protein, and variants thereof, are described wherein 213P1F11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 213P1F11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 213P1F11 gene ... 02/15/07 - 20070037744 - Human cathelicidin antimicrobial peptides Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents. ... 02/15/07 - 20070037743 - Novel conotoxin modulating sodium channels A 26 residue peptide (Am2766) with the sequence CKQAGESCDIFSQNCCVGTCAFICIE-NH2 has been isolated and purified from the venom of the molluscivorous snail, Conus amadis, collected of the southeastern coast of India. Chemical modification and mass spectrometric studies establish that Am2766 has three disulfide bridges. Cterminal amidation has been demonstrated by mass ... 02/15/07 - 20070037742 - Use of follicle stimulating hormone for reduction of spermatozoa chromosomal aberration in males The present invention relates to the use of a substance having a FSH activity for reducing gamete chromosomal alterations in a male, more specifically in men suffering from spermatozoa aneuploidy. ... 02/15/07 - 20070037741 - Novel compositions and methods for the treatment of immune related disease The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related disease. ... 02/15/07 - 20070037740 - Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of alphacalcidol, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple ... 02/15/07 - 20070037739 - Compounds useful in coating stents to prevent and treat stenosis and restenosis At least one bioactive agent is locally delivered to a location where a stent is implanted within a lumen in a patient's body. The bioactive agent includes a: DNA minor groove binder (such as CC-1065 or Duocarmycin); apocynin; RGD peptide (such as RGDfV); stilbene compound (such as resveratrol); camptothecin; des-aspartate ... 02/08/07 - 20070032429 - Methods of using retro-inverso peptides derived from interleukin-6 This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO: 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the ... 02/08/07 - 20070032428 - Novel antimicrobial agents A novel class of antimicrobial polymeric agents which are designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms, ... 02/08/07 - 20070032427 - Methods and compositions for preserving the viability of photoreceptor cells Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a neuroprotective agent, for example, a substance capable of suppressing endogenous calcineurin or constitutively active calcineurin, inhibiting cleavage of calcineurin to constitutively active calcineurin, and/or ... 02/08/07 - 20070032426 - Therapeutic and diagnostic methods for ulcerative colitis and associated disorders This invention relates to the field of therapy and diagnostic methods for ulcerative colitis. Specifically, the method comprises administering a compound or recombinant protein that inhibits interaction between CEP and human tropomyosin. Also included in the invention are methods to screen for drugs useful in treating ulcerative colitis and diagnostic ... 02/08/07 - 20070032425 - Compositions for diabetes treatment and prophylaxis Gurmarin containing compositions are useful for modulation of glucose metabolism and the treatment of diabetes. Glucose metabolism in a human patient is regulated by isolated gurmarin-containing dosage forms that contain optionally a non-metabolizable polysaccharide such as the exudate of Sterculia urens. ... 02/08/07 - 20070032424 - Stimulators of factor x activated (fxa) as new topical antihemorrhagic agents The activated coagulation Factor X (FXa) stimulating agents may be used in the treatment of hemorrhages in a subject. Compounds and combinations are described which are particularly useful for the topical treatment of hemorrhaging in healthy subjects or in patients with hemorrhagic diathesis. ... 02/08/07 - 20070032423 - Methods and compositions for modulating somatolactogenic functions Compositions containing cyclophilin B, mutants of cyclophilin B or inhibitors of cyclophilin B and methods of using these compositions to modulate somatolactogenic function are provided. ... 02/08/07 - 20070032422 - Methods, compositions and articles of manufacture for contributing to the treatment of cancers Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent. ... 02/08/07 - 20070032421 - Methods and compositions relating to cystatin c A method of treating amyloidoses by administering an effective amount of a cystatin C composition. A method of preventing and inhibiting Aβ oligomerization by administering an effective amount of a cystatin C composition. A composition for inhibiting Aβ oligomerization including an effective amount of a cystatin C composition. A method ... 02/08/07 - 20070032420 - Treating diabetes with glucagon-like peptide-1 secretagogues In general this invention can be viewed as encompassing novel methods of treating diabetes and insulin resistance. The inventors have made the discovery that increasing secretion of endogenous glucagon-like peptide-1 (GLP-1) in combination with inhibiting the activity of dipeptidyl peptidase I (DPP-IV) can have a significant impact on hyperglycemia and ... 02/08/07 - 20070032419 - Fusion polypeptides, and use thereof in antivascular tumor therapy The present invention relates to fusion polypeptides, comprising at least two peptides. The invention further relates to the use of these fusion proteins in antivascular therapy of neoplastic diseases and to their use I the production of a drug for the treatment of neoplastic diseases. ... 02/08/07 - 20070032418 - Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same Lead compounds were obtained in a high throughput screen (HTS) of angiogenin (ANG; a potent inducer of angiogenesis) enzyme activity, an RNase. One lead was shown to delay appearance of tumors in an animal tumor system, and to reduce the number of animals having tumors. Several lead compound analogs were ... 02/08/07 - 20070032417 - Peptides and therapeutic uses thereof Conformationally constrained peptides that mimic BH3-only proteins, compositions containing them and their use in the regulation of cell death are disclosed. The conformationally constrained peptides are capable of binding to and neutralising pro-survival Bcl-2 proteins. Processes for preparing the conformationally constrained peptides and their use in the treatment and/or prophylaxis ... 02/08/07 - 20070032416 - Chorionic somatomammotropin hormone splice variants This invention relates to novel proteins, termed INSP100 and INSP104, herein identified as novel splice variants of human Chorionic somatomammotropin hormone 2 (hCS-B; Q14407) and human Chorionic somatomammotropin hormone 1 (hCS-A; P01243) respectively and to the use of these proteins and nucleic acid sequences from the encoding genes in the ... 02/08/07 - 20070032415 - Compositions, splice variants and methods relating to breast specific genes and proteins The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic breast cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of ... 02/08/07 - 20070032414 - Human secreted proteins The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating cardiovascular diseases, disorders, and/or conditions related thereto. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells and ... 02/08/07 - 20070032413 - Human secreted proteins The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, ... 02/01/07 - 20070027085 - Microencapsulation and sustained release of biologically active polypeptides This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide, a sugar and ... 02/01/07 - 20070027084 - Novel integrin ligand itgl-tsp ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retmopathy), restenosis, ... 02/01/07 - 20070027083 - Human growth hormone aqueous formulation A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations. ... 02/01/07 - 20070027082 - Intracellular interleukin-1 receptor antagonist and uses thereof Matrix metalloproteinases are major mediators of tissue destruction in various chronic inflammatory disorders. The present invention demonstrates that over- expression of intracellular isoform of IL-1 receptor antagonist confers to recipient cells resistance to signaling pathways of proinflammatory cytokines (such as tumor necrosis factor alpha and IL-1 beta) that induce matrix ... 02/01/07 - 20070027081 - Mechanisms of osteoinduction by lim mineralization protein-1 (lmp-1) The present invention relates to the methods and compositions for the treatment of subjects having compromised bone conditions. Specifically, the invention relates to combinatorial therapeutic strategies including small molecules and peptide mimics of LIM mineralization proteins, particularly LMP-1, to overcome the dose-related translational barriers for BMP-2 therapeutics. ... 02/01/07 - 20070027080 - Method for treatment of vitiligo Synergistic therapies for the treatment of vitiligo are provided. The major therapies for the treatment of vitiligo—a pigmentary disorder characterized by patchy depigmentation of skin are Psoralens plus UV-A, steroids. Basic fibroblast growth (bFGF) peptide lotion or surgical procedures. Psoralens plus UV-A is effective in about 50% of cases, steroids ... 02/01/07 - 20070027079 - Ghrp 2 strips The products that exist on the market today that produce the same results are with injection. This new product, HGH Strips, is taken orally through strips that are placed on the back of the toungue. HGH Strips is scientifically developed with GHRP-2 (Growth Hormone Releasing Peptide-2), L-Lysine, L-Argenin and L-Valine ... 02/01/07 - 20070027078 - Isolated proteins from a traditional chinese medicine yuzhu and use thereof Disclosed is an isolated protein from the Chinese medicinal herb, Yuzhu, Polygonatum odoratum (Liliaceae). The protein disclosed is an effective agent showing potent antiviral activities while demonstrating antiproliferative effect on HL-60 leukemia and MCF-7 breast cancer cell lines in vitro. A method of obtaining the target protein and use thereof ... 02/01/07 - 20070027077 - Pharmaceutical compositions comprising factor vii polypeptides and factor xi polypeptides Compositions comprising a factor VII or factor VII-related polypeptide and a factor XI or factor XI-related polypeptide, kits comprising the same, and methods of using such compositions (e.g., in the treatment of bleeding conditions) are provided ... 02/01/07 - 20070027076 - Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma According to a first aspect the invention relates to the use of fumaric acid derivatives selected from the group consisting of dialkyl fumarates, monoalkyl hydrogen fumarates, fumaric acid monoalkyl ester salts, fumaric acid monoamides, monoamido fumaric acid salts, fumaric acid diamides, monoalkyl monoamido fumarates, carbocyclic and oxacarbocyclic oligomers of these ... 02/01/07 - 20070027075 - Compositions and methods for targeted drug delivery The present invention provides for methods and compositions for transporting agents and macromolecules across biological membranes. In one embodiment, the invention relates to a method for enhancing transport of a selected agent across a biological membrane, wherein a biological membrane is contacted with a composition containing a biologically active rotaxane ... 02/01/07 - 20070027074 - Novel peptides that bind to the erythropoietin receptor The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also ... 02/01/07 - 20070027073 - Long-acting derivatives of pyy agonists The invention provides a PYY agonist derivative of the formula: (X)n-Z, wherein X is a radical 9-fluorenylmethoxy-carbonyl (Fmoc) or 2-sulfo-9-fluorenyl-methoxycarbonyl (FMS), Z is the residue of a PYY agonist linked to the radical X through an amino or hydroxyl group, and n is 1 to 3, or a pharmaceutically acceptable ... 01/25/07 - 20070021344 - Stabilized teriparatide solutions A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH (1-34), mannitol, an acetate or tartrate buffering agent and ... 01/25/07 - 20070021343 - Stabilized teriparatide solutions A stabilized pharmaceutical composition in the form of a solution for parenteral administration of a parathyroid hormone is described wherein the therapeutically active ingredient is stabilized with a buffer and a polyol. Preferred preparations contain in an aqueous solution human PTH(1-34), mannitol, an acetate or tartrate buffering agent and m-cresol ... 01/25/07 - 20070021342 - Wound healing Methods for accelerating and/or improving wound healing in a subject by administering vascular endothelial growth factor (VEGF) are provided. ... 01/25/07 - 20070021341 - Treatment of autoimmune conditions with copolymer 1 and related copolymers The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one ... 01/25/07 - 20070021340 - Use of blood coagulation factor xiii for treating hemophilia a A patient having hemophilia A is treated by administering factor XIII generally in conjunction with factor VIII or desmopressin. ... 01/25/07 - 20070021339 - Glp-1 pharmaceutical compositions The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues. ... 01/25/07 - 20070021338 - Stabilised compositions of factor vii The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature. ... 01/25/07 - 20070021337 - Novel agent for inducing apoptosis comprising msx1 or a gene encoding the same as an active ingredient The present invention relates to a novel use of Msx1 protein or a nucleotide encoding the same for inducing apoptosis. The Msx1 of the present invention induces apoptosis through direct interaction with p53 via a homeodomain and such interaction leads to increased stability, and/or nuclear localization of p53 in cells. ... 01/25/07 - 20070021336 - Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis The present invention relates generally to the novel use of GLP-1, including analogs, and agonists, to prevent cardiac myocyte apoptosis. The present invention relates to methods for using GLP-1 for the treatment of conditions associated with cardiac myocyte apoptosis. The present invention further relates to improving the efficiency of cardiac ... 01/25/07 - 20070021335 - Agent for improving mental disorders The present invention provides an agent for improving mental disorders due to cerebral dysfunction and an agent for inhibiting vascular hyperpermeability each containing a hepatocyte growth factor. The agent for improving mental disorders according to the present invention is useful in improving mental disorders, particularly decline in learning and memory ... 01/25/07 - 20070021334 - Class iii slrp agonists for the reduction of blood vessel formation The invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the inhibition of blood vessel formation. In addition the invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a ... 01/25/07 - 20070021333 - Pharmaceutical compositions based on anticholinergics and soluble tnf receptor fusion proteins The present invention relates to novel pharmaceutical compositions based on anticholinergics and soluble TNF receptor fusion proteins, processes for preparing them and their use in the treatment of respiratory diseases. ... 01/25/07 - 20070021332 - Helminth-derived antigens having capacity of providing protection against parasites The primary objective of the present invention is the development of new mutant forms of the Sm14 protein, for producing a greater production volume. The recombinant proteins here obtained were capable of providing protection against schistosome and fasciola infection. The level of protection of Sm14 recombinant proteins obtained in the ... 01/18/07 - 20070015709 - Method for treating hemophilia b Use of factor XIII for treating hemophilia B. A patient having hemophilia B is treated by administering factor XIII, generally in conjunction with factor IX. ... 01/18/07 - 20070015708 - Methods and compositions for inhibiting tumor growth and angiogenesis The invention provides compositions comprising angiogenesis inhibitors and RGD-containing plasma adhesion proteins in a pharmaceutical carrier. This invention also provides methods of inhibiting angiogenesis, tumor growth and metastasis by administering angiogenesis inhibitors in combination with RGD-containing plasma adhesion proteins in a pharmaceutical carrier. ... 01/18/07 - 20070015707 - Neuroprotective effect of activin in animals exposed to hypoxia/ischemia This invention includes embodiments comprising activin and analogs of activin for neuronal rescue in patients having neurons that are subject to death and/or degradation as a result of neurological diseases. In certain embodiments, an activin receptor agonist can be useful for treating neuralogical diseases such as Alzheimer's Disease, Parkinson's Disease ... 01/18/07 - 20070015706 - Bifunctional variants of recombinant tissue-type plasminogen activator with platelet aggregation inhibitory activity The present invention provides improved tPA variants having significantly reduced susceptibility to inhibition and increased affinity for platelet integrin as compared with the wild-type tPA. The present invention also provides compositions comprising the tPA variants and polynucleotides, vectors, and host cells for producing the same as well as methods of ... 01/18/07 - 20070015705 - Modified annexin proteins and methods for their use in platelet storage and transfusion Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage, enhancing the survivability of platelets during storage or transfusion and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell ... 01/18/07 - 20070015704 - Nucleic acid and corresponding protein entitled 238p1b2 useful in treatment and detection of cancer A novel gene (designated 238P1B2) and its encoded protein, and variants thereof, are described wherein 238P1B2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 238P1B2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 238P1B2 gene ... 01/18/07 - 20070015703 - Adamts13-containing compositions having thrombolytic activity This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the ... 01/18/07 - 20070015702 - Method of treatment and/or prevention of neuropathic pain The present invention relates to a method of treating and/or preventing neuropathic pain, comprising administering calcitonin continuously. The present invention can provide a drug effective for the treatment of various neuropathic pains. Providing a drug having an action effective on neuropathic pain and having low toxicity. An agent for treating ... 01/18/07 - 20070015701 - Macromolecular conjugates of bone morphogenetic protein-7 A modified bone morphogenetic protein (BMP, also referred to as bone morphogenic protein) composition is described. The bone morphogenetic protein, in one embodiment, is BMP-7 which is chemically modified with a hydrophilic polymer, such as poly(ethylene glycol). ... 01/18/07 - 20070015700 - Mammalian genes modulated during fasting and feeding Genes are disclosed that are differentially-regulated during feeding and fasting cycles. These genes, and their encoded polypeptides are useful to combat obesity. ... 01/18/07 - 20070015699 - Variants of traf2 which act as an inhibitor of tnf-alpha (tnfalpha) signaling pathway The present invention relates to variants of TRAF2 which demonstrate the ability to inhibit the TNF α signaling pathway. In particular, applicants have isolated a splice variant of TRAF2 referred to hereinafter as “TRAF2 truncated” or “TRAF2TR” and a TRAF2 expression construct with enhanced dominant negative properties, hereafter referred to ... 01/18/07 - 20070015698 - Treatment of skin, and wound repair, with thymosin beta 4 Compositions and methods for treatment of skin utilizing thymosin β4. ... 01/18/07 - 20070015697 - Enhanced ocular neuroprotection and neurostimulation An ocular method comprising non-systemic localized ocular administration of a pharmaceutically acceptable formulation and effective concentration of at least one neurostimulatory and/or neuroprotective macrolide or other agent for a duration sufficient to enhance viability, confer protection, reduce degeneration of retinal neural cells. The method is used in a patent having ... 01/18/07 - 20070015696 - 621 human secreted proteins The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating cancer and other hyperproliferative diseases and disorders. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and ... 01/18/07 - 20070015695 - Three-dimensional structures of tall-1 and its cognate receptors and modified proteins and methods related thereto Disclosed are TALL-1 and TALL-1 receptor protein homologues (agonists and antagonists) designed based on the three-dimensional structure of sTALL-1, eBCMA and eBAFF-R; agonist homologues of APRIL; methods of using wild-type APRIL to inhibit the activity of TALL-1; compositions comprising such homologues, nucleic acid molecules encoding such homologues, and therapeutic methods ... 01/11/07 - 20070010449 - Method of treatment of hemorrhagic disease using a factor viia/tissue factor inhibitor The present invention provides methods of treating hemorrhagic fevers where selective inhibitors of fVIIa/TF are used as a treatment for hemorrhagic fevers and have therapeutic effects which include ameliorating and/or preventing coagulopathy and inflammatory responses. These inhibitors include certain proteins which are part of a family termed Nematode-Extracted Anticoagulant Proteins ... 01/11/07 - 20070010448 - Drug targets in candida albicans The present invention is concerned with the identification of genes or functional fragments thereof from Candida albicans which are critical for growth and cell division and which genes may be used as selective drug targets to treat Candida albicans associated infections. Novel nucleic acid sequences from Candida albicans are also ... 01/11/07 - 20070010447 - Methods and compounds for the treatment of mucus hypersecretion A method of treating mucus hypersecretion, the causative factor in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD, comprises administering a compound that inhibits exocytosis in mucus secreting cells or neurones that control or direct mucus secretion. Also described is a compound, for use in the ... 01/11/07 - 20070010446 - Methods for treating inflammation using thyroid stimulating hormone Thyroid stimulating hormone has been shown to have anti-inflammatory activity. Polypeptides of thyroid stimulating hormone have a novel use as an anti-inflammatory agent as a stand-alone therapy, or in conjunction with other anti-inflammatory agents. In addition, thyroid stimulating hormone can be used to potentiate the anti-inflammatory activity of glucocorticoid treatment. ... 01/11/07 - 20070010445 - Administration of hypocretin-1 for treatment of narcolepsy The invention provides compositions and methods for treatment of sleep disorders. Such methods entail administering to the patient a therapeutically effective dosage regime of an agonist of a hypocretin 1 (Hcrt-1) receptor to a peripheral tissue of the patient, and monitoring the condition of the patient responsive to the treatment, ... 01/11/07 - 20070010444 - Novel mediator of neurotransmitter and psychostimulant responses The present invention provides polypeptides (termed “egl-28 polypeptides”) that modulate neurotransmitter- and psychostimulant-induced responses. The invention also provides methods of modulating such responses, as well as and anti-egl-28 antibodies. The invention encompasses related polynucleotides, vectors, host cells, production methods, and compositions. Moreover, the invention includes methods for prescreening or screening ... 01/11/07 - 20070010443 - Monitoring and modulating hgf/hgfr activity Provided are methods and compositions for the modulation of hepatocyte growth factor activity to regulate lymphatic vessel development and function. Methods and composition for the monitoring and treatment of skin disorders, lymphedema, and metastatic cancers are disclosed. Also described are methods of identifying inhibitors of hepatocyte growth factor dependent lymphangiogenesis. ... 01/11/07 - 20070010442 - Inhibitor of vascular endothelial cell growth factor The vascular endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth ... 01/11/07 - 20070010441 - Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport ... 01/11/07 - 20070010440 - Local treatment of bone defects A method of local treatment of specific bone defects such as osteoporosis or bone cysts comprises the step of local administration of a formulation comprising a fusion peptide containing a first domain comprising PTH or BMP 2 or BMP 7, and a second domain comprising a covalently crosslinkable substrate domain; ... 01/11/07 - 20070010439 - Production of human parathyroid hormone from microorganisms The invention provides recombinant plasmids containing in DNA sequences coding for human preproparathyroid hormone. The invention further provides microorganisms, for example E. coli, transformed by these plasmids. The invention also provides a plasmid for insertion into yeast and a transformed yeast in which the plasmid contains DNA coding for parathyroid ... 01/11/07 - 20070010438 - Tumor treatment using beta-sheet peptides and radiotherapy The invention relates to the use of designed β-sheet peptides together with radiation therapy for cancer treatment. The β-sheet peptides, which were designed using portions from several α-chemokines, exhibit activity as radiosensitizing agents, and have demonstrated synergism with radiation therapy for cancer treatment. The β-sheet peptides also exhibit activity as ... 01/11/07 - 20070010437 - Amino acid based compositions for the treatment of pathological conditions distinguised by insufficient mitochondrial function Described herein are compositions suitable for the treatment of pathological conditions distinguished by ‘insufficient or reduced mitochondrial function. The compositions comprise, as principal active ingredients, the amino acids leucine, isoleucine and valine. Preferably envisaged, as further active ingredients, are the amino acids threonine and lysine, and possibly histidine, phenylalanine, methionine, ... 01/11/07 - 20070010436 - Remedy for cardiomyopathy The present invention provides a cardiomyopathy therapeutic agent that contains hepatocyte growth factor (HGF) and gelatin hydrogel, and gradually releases HGF, which is useful in treating cardiomyopathy. ... 01/11/07 - 20070010435 - Method for treating amyloid disease Disclosed herein are methods for treating amyloid disease in humans by clearing amyloid peptides from one or more bodily fluids such as, e.g., blood, of a patient. In particular, the methods are based on the administration capable of binding to amyloid-beta (Aβ) or on dialysis of blood or plasma exchange ... 01/11/07 - 20070010434 - Novel compositions and methods for the treatment of immune related diseases The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. ... 01/11/07 - 20070010433 - Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease The present invention relates to use of compounds directed to inhibiting expression and/or proteolytic processing semaphorins SEMA3E and/or sema3E and/or activation of a receptor by a proteolytic product of said semaphorins for the manufacture of a medicament for prevention, treatment diagnosis and/or prognosis of an invasive disease. The invention features ... 01/11/07 - 20070010432 - Heat shock protein 90 activator This invention relates the identification of a novel co-factor (termed ‘Aha1’) that interacts with the molecular chaperone Heat shock protein 90 (Hsp90) and stimulates Hsp90 activity. Various assay methods and therapeutic applications based on this interaction are provided. ... 01/04/07 - 20070004630 - Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present ... 01/04/07 - 20070004629 - K9 and equine joint health food supplement and method of administering Kolla2 powder compositions, methods of preparing the compositions, and use of the compositions in treating degenerative joint diseases, joint defects, hip displasia, and osteoarthritis. The compositions are orally administered to K9's and equines in need of cartilage cell repair in a daily dietary food supplement. ... 01/04/07 - 20070004628 - Compositions and methods for nerve regeneration This disclosure demonstrates that p45 promotes rapid regeneration of CNS nerves and axons (for example, in the corticospinal tract and/or raphespinal tract) and locomotor functional recovery following complete spinal cord transection in an adult subject. This remarkable discovery as well as disclosed mapping of p45 functional regions enables, for instance, ... 01/04/07 - 20070004627 - Compounds and methods for treatment of cancer The invention relates to methods and compounds for treating or preventing cancer. Methods for treating or preventing cancer, for inhibiting tumor growth, reducing tumor volume, inhibiting tumor progression, inhibiting metastasis, and improving survival are provided herein. ... 01/04/07 - 20070004626 - Methods and compositions for treating degenerative bone disorders The present disclosure provides methods and compositions using Syk inhibitory compounds for treating degenerative bone disorders and as prophylactic treatment to prevent bone loss. These treatments may reduce the fracture risk associated with bone loss and compromised bone strength. ... 01/04/07 - 20070004625 - Use of complement inhibitory proteins to treat spinal cord injury Trauma to the spinal cord initiates an inflammatory response that results in secondary injury to the surrounding tissue, thereby exacerbating the effects of the initial injury. These secondary injury effects are contributed to, in part, by the activation of complement and the associated inflammatory reaction at the site of injury. ... 01/04/07 - 20070004624 - Methods for modulating bone tissue formation, orthogenic agents and pharmaceutical compositions The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts, including bone formation enhancing pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean bone ... 01/04/07 - 20070004623 - Use of hydroxylated amino acids for treating diabetes This invention relates to methods and compositions for treating diabetes, which involve the use of hydroxylated amino acids, such as 4-hydroxyisoleucine, and one or more additional antidiabetic agents. ... 01/04/07 - 20070004622 - Imidazole derivative, process for producing the same, and use The present invention relates to the use of a peptide that interacts with the αvβ3 integrin of endothelial cells. More particularly, the invention relates to a method for inhibiting endothelial cell adhesion, endothelial cell migration and/or angiogenesis, using a peptide consisting of at least 18 amino acids, comprising tyrosine-histidine (TY) ... 01/04/07 - 20070004621 - Bex4 nucleic acids, polypeptides, and method of using Bex4 nucleic acids and polypeptides are provided, as are methods of using the nucleic acids and polypeptides. ... 01/04/07 - 20070004620 - Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus A method of treating or preventing a pathological condition of the uterus in an female individual, the method comprising administering to the individual at least one agent that prevents PGF2α, having its effect on the FP receptor. Typically, the pathological condition is uterine cancer, fibroids or endometriosis. ... 12/28/06 - 20060293241 - Pharmaceutical composition comprising a factor vii polypeptide and epsilon-aminocaproic acid The present invention relates to compositions or kits comprising factor VII or a factor VII-related polypeptide and epsilon-aminocaproic acid, and the use thereof for the treatment of bleeding episodes or enhancement of hemostasis. ... 12/28/06 - 20060293240 - Human sef isoforms and methods of using same for cancer diagnosis and gene therapy A method and pharmaceutical compositions useful for inhibiting the growth of solid tumors are provided. Specifically, the method is effected by administering to a subject in need thereof an agent capable of upregulating the expression level and/or activity of at least a functional portion of Sef, wherein the functional portion ... 12/28/06 - 20060293239 - Treatment and diagnosis of insulin-resistant states Dickkopf-5 (Dkk-5) protein is administered in effective amounts to treat disorders involving insulin resistance, such as non-insulin-dependent diabetes mellitus (NIDDM) or obesity. Also provided is a method of diagnosing insulin resistance and related disorders using Dkk-5 as a measure, and kits for diagnosis and treatment, as well as hybridomas producing ... 12/28/06 - 20060293238 - Inactivation resistant factor viii The present invention provides novel purified and isolated nucleic acid sequences encoding procoagulant-active FVIII proteins. The nucleic acid sequences of the present invention encode amino acid sequences corresponding to known human FVIII sequences, wherein residue Phe309 is mutated. The nucleic acid sequences of the present invention also encode amino acid ... 12/28/06 - 20060293237 - Psiepsilonrack peptide composition and method for protection against tissue damage due to ischemia A method of reducing damage to cells and tissue caused by an ischemic or hypoxic event is disclosed. The method includes administering to the cell or tissue, either in vivo or ex vivo, ψεRACK peptide. The peptide can be administered before, during or after the ischemic or hypoxic event. ... 12/28/06 - 20060293236 - Injectable osteogenic formula and method of using same Formulations and methods for growing bone in a site specific location using an osteogenic molecule such as a prostaglandin, and a delivery vehicle which is preferably a polymer matrix. ... 12/28/06 - 20060293235 - Hgf beta chain variants The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators. ... 12/28/06 - 20060293234 - Therapeutic peptides for the treatment of metastatic cancer Interaction between MUC1 and β-catenin can be interrupted using polypeptides or antibodies that specifically bind to the binding site on MUC1. Interruption provides the beneficial effect of inhibiting, reducing, and/or retarding invasiveness and metastasis. Fusion polypeptides and antibodies are provided to achieve a therapeutic effect. ... 12/28/06 - 20060293233 - Compositions and methods for modulating body weight and treating obesity-related disorders The present invention relates to compositions and methods for regulating body weight, and for treating conditions associated with obesity, particularly, obesity-related diabetes. The present invention is premised on the discovery that body weight can be effectively regulated by modulating the levels and/or activities of two gut hormones, PYY and ghrelin. ... 12/28/06 - 20060293232 - Hybrid polypeptides with selectable properties The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are ... 12/28/06 - 20060293231 - Method for enhancing bone formation This invention provides a method for facilitating bone formation in a subject comprising delivering to a bone formation-requiring site a composition of matter comprising platelet-rich plasma, calcium, a PAR-activating agent and a bone forming material. This invention further provides a method for facilitating bone formation in a subject comprising (a) ... 12/28/06 - 20060293230 - Expression and secretion of icil-1 receptor antagonist type ii Novel glycosylated intracellular IL-1 receptor antagonist type II (icIL-1ra-II) is expressed and secreted in mammalian cells transformed with an expression vector where icIL-1ra-II is secreted by expressing icIL-1ra-II fused to the human growth hormone signal peptide. Also disclosed are a pharmaceutical composition containing glycosylated icIL-1ra-Il as an active ingredient and ... 12/28/06 - 20060293229 - Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor Site-specific isotopically-labeled valine, leucine, and isoleucine and biosynthetic precursors for these amino acids are provided. The amino acids are labeled with 13C or 14C at the methyl group carbon atom(s) most remote from the carboxyl group. Also disclosed are the biochemical precursors of these labeled amino acids, 2-keto-4-(nC) butyric acid ... 12/28/06 - 20060293228 - Therapeutic compositions and methods using transforming growth factor-beta mimics The invention provides methods, compositions, and kits for treating a variety of conditions using substances that display one or more activities of transforming growth factor-β (TGF-β mimics). Conditions include skin conditions, wounds, and the need for soft tissue augmentation. Compositions that may be used to treat such conditions contain a ... 12/28/06 - 20060293227 - Cosmetic compositions and methods using transforming growth factor-beta mimics The invention provides methods, compositions, and kits for a variety of cosmetic uses, where the methods, compositions and kits utilize substances that display one or more activities of transforming growth factor-β (TGF-β mimics). Compositions, methods, and kits contain TGF-β mimics. ... 12/28/06 - 20060293226 - Medicament and use thereof for tumor therapy The invention relates to a medicament for tumor therapy, containing a first and a second molecule in an effective concentration, the first molecule representing a1) Annexin V or a molecule that is largely similar thereto, or a2) an effective fragment of Annexin V or the molecule that is largely similar ... 12/28/06 - 20060293225 - Gmg-2 polynucleotides and polypeptides and uses thereof The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, homotrimer of GMG-2 polypeptide fragment comprising globular domain and all or part of GMG-2 collagen-like region, has been identified that has utility for reducing body mass, for ... 12/21/06 - 20060287237 - Rhob as a suppressor of cancer cell growth, cell transformation, and metastasis The present invention concerns the use of the protein RhoB and its variants to inhibit cancer cell growth, migration, invasion, metastasis, malignant cell transformation, and/or to modulate oncogenic signaling, wherein introducing RhoB directly, or indirectly via a nucleic acid sequence encoding RhoB, into a malignantly transformed cell or a cancerous ... 12/21/06 - 20060287236 - Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases Methods and compositions are provided for the diagnosis and treatment of iron overload diseases and iron deficiency diseases. ... 12/21/06 - 20060287235 - Crystallization of igf-1 Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, optionally also recrystallizing and isolating the crystalline IGF-1. In addition, a method ... 12/21/06 - 20060287234 - Wound healing Methods for accelerating and/or improving wound healing in a subject by administering vascular endothelial growth factor (VEGF) are provided. ... 12/21/06 - 20060287233 - Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells The present invention provides materials and methods for the treatment of diabetes. Using the materials and methods of the invention, the loss of pancreatic β-cells can be slowed and/or prevented. In addition, the materials and methods of the invention can be used to regenerate pancreatic β-cells. ... 12/21/06 - 20060287232 - Antimicrobial peptides Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and ... 12/21/06 - 20060287231 - Therapeutic uses of kallikreins The present invention relates to therapeutic applications of kallikreins and compositions containing them for treating, preventing and/or ameliorating cancers, especially epithelial cancers, such as ovarian, breast and cervical cancer. ... 12/21/06 - 20060287230 - Compositions which can be used for regulating the activity of parkin The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating, ... 12/21/06 - 20060287229 - Novel cd40 variants The invention concerns CD40 skipping 5 nucleic acid sequences and amino acid sequences obtained by alternative splicing of CD40, pharmaceutical compositions comprising said sequences and methods for treatment of a disease, wherein a beneficial therapeutic effect is achieved by the up regulation of the CD40-R-CD40-L interaction. An antibody capable of ... 12/21/06 - 20060287228 - Expression of active human factor ix in mammary tissue of transgenic animals Recombinant Factor IX characterized by a high percentage of active protein can be obtained in the milk of transgenic animals that incorporate chimeric DNA molecules according to the present invention. Transgenic animals of the present invention are produced by introducing into developing embryos DNA that encodes Factor IX, such that ... 12/21/06 - 20060287227 - Gonadal function improving agents Metastin, compounds that promote the activity of metastin or its receptors and the like are excellent gonadal function improving agents, ovulation inducers or promoters, gonadotropic hormone secretion promoters, gonadotropic hormone secretion inhibitors, sex hormone secretion promoters, sex hormone secretion inhibitors, etc., and can be used as agents for preventing/treating sterility, ... 12/21/06 - 20060287226 - Characterization of a membrane estrogen receptor The present invention discloses the identification of a novel membrane associated estrogen receptor, termed mER. The membrane associated receptor is involved in rapid signal transduction. Amino acid sequences, nucleic acid sequences, vectors, and host cells are also discussed. Additionally, methods of detecting agonists and antagonists for the receptor are disclosed ... 12/14/06 - 20060281681 - Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of Respiratory Distress Syndrome (RDS), Bronchopulmonary dysplasia (BPD), chronic lung disease and/or pulmonary fibrosis, Asthma and Chronic Obstructive Pulmonary Disease (COPD). More particularly, ... 12/14/06 - 20060281680 - Methods and compositions for modulating vascular integrity The invention provides methods and compositions useful for modulating vascular integrity. ... 12/14/06 - 20060281679 - Human fgf-23 gene and gene expression products This invention relates to human fibroblast growth factor (hFGF-23), to cleavage products of hFGF-23, and to variants thereof and to polynucleotides encoding FGF-23. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating skin, brain and ... 12/14/06 - 20060281678 - Novel inhibitor of angiogenesis, tumor progression, and metastasis targeting ras signalling pathway The present invention relates to a novel use of thymosin β10 protein for anti-angiogenesis, anti-tumor progression, and anti-metastasis by targeting a Ras signaling pathway. Particularly, thymosin β10 protein reduces the generation of a Ras-GTP/Raf complex by sequestering Ras-GTP or by interfering with the binding of Ras-GTP to Raf through a ... 12/14/06 - 20060281677 - Compositions and methods for intracellular delivery of biotinylated cargo The invention provides compositions for intracellular delivery of biotinylated cargo. The compositions comprise a complex formed between (a) a fusion protein comprising a protein transduction domain linked to streptavidin and (b) a biotinylated cargo for intracellular delivery. In some embodiments, the protein transduction domain comprises the protein transduction domain of ... 12/14/06 - 20060281676 - Agent and method for the treatment and prevention of tse and method for the production of said agent The invention relates to an agent and/or pharmaceutical active ingredient and to a method for the treatment, prevention and diagnosis of TSE, and to a method for the production of an agent and/or pharmaceutical active ingredient. According to the invention, peptides and/or nucleotide sequences coding for said peptides are provided ... 12/14/06 - 20060281675 - Somatogenic therapy using a 20kda placental variant of growth hormone Embodiments of the present invention provide improved methods of treating conditions requiring human growth hormone (hGH) therapy, whereby the beneficial effects of hGH such as growth promotion and lipolysis are retained and unwanted properties are reduced or eliminated. In particular, it is directed at a method of treatment whereby the ... 12/14/06 - 20060281674 - S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment The present invention relates to a method and composition for inducing lymphocyte proliferation and migration, and for reducing the risks of microbial infections in patients immuno-supressed. The present invention particularly relates to the use of S100 protein, such as MRP, to induce the proliferation, differentiation and release of immune cells ... 12/14/06 - 20060281673 - Novel peptide inhibitor of hiv fusion that disrupts the internal trimeric coiled-coil of gp41 This invention relates to a novel peptide inhibitor of a HIV fusion that disrupts the internal trimeric coiled-coil of gp41, to a pharmaceutical composition that comprise this inhibitor, and to methods of treating immunodeficiency disease, especially HIV, that employ such a pharmaceutical composition. ... 12/14/06 - 20060281672 - Dec-205 (ly 75)/dcl-1 intergenic splice variants associated with hodgkin's disease, and uses thereof The inventors have identified intergenically spliced DEC-205/DCL-1 mRNAs, which encode the intact DEC-205 ectodomain together with an additional carbohydrate recognition domain, a transmembrane domain and a cytoplasmic domain derived from DCL-1. These DEC-205/DCL-1 intergenic splice variants were identified on Reed-Sternberg cells and thus have application in the therapy and investigation ... 12/07/06 - 20060276399 - Peptide antagonists of zonulin and methods for use of the same Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions. ... 12/07/06 - 20060276398 - Combined use of factor vii polypeptides and factor viii polypeptides The invention concerns a pharmaceutical preparation comprising a factor VII or factor VII-related polypeptide and a factor VIII or factor VIII-related polypeptide. The invention also concerns use of a factor VII or factor VII-related polypeptide and a factor VIII or factor VIII-related polypeptide for manufacture of a medicament for pharmaceutical ... 12/07/06 - 20060276397 - Crystallization of igf-1 Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, optionally also recrystallizing and isolating the crystalline IGF-1. In addition, a method ... 12/07/06 - 20060276396 - Albumin fusion proteins The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention ... 12/07/06 - 20060276395 - Pharmaceutical compositions of adiponectin variants and methods of storage 1. A composition comprising an adiponectin variant at a concentration of at least 2.0 mg/mL, and a pharmaceutically acceptable carrier, wherein less than 20% of said adiponectin variant would aggregate after storage at 4° C. for one week in 10 mM PO4, 150 mM NaCl buffer. ... 12/07/06 - 20060276394 - Methods and compositions for treating neurological disorders The present invention relates generally to the fields of neuroscience, growth factors and depression. More particularly, the present invention addresses the need in the art for methods and compositions for treating neurological disorders such as depression, anxiety, panic disorder, bi-polar disorder, insomnia, obsessive compulsive disorder, dysthymic disorder and schizophrenia. In ... 12/07/06 - 20060276393 - Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders Provided herein are methods and compositions for treating or preventing neurodegenerative disorders or blood coagulation disorders. Methods may comprise modulating the activity or level of a sirtuin, such as SIRT1 or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, ... 12/07/06 - 20060276392 - Treatments employing neuronal exocytosis-inhibiting peptides The peptide has a sequence of 3 to 30 adjacent aminoacids from the amino end of protein SNAP-25 and is useful as neuronal exocytosis inhibitor. The cosmetic and pharmaceutical compositions contain said peptide and optionally one or more peptides from the carboxyl end of SNAP-25. Said compositions are suitable for ... 12/07/06 - 20060276391 - Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization The present invention concerns the use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization. Partcularly, the above-mentioned diseases are (wet) age-related macular degeneration, (proliferative) diabetic retinopathy, neovascular glaucoma, retinal vein occlusion, or ... 12/07/06 - 20060276390 - Combined treatments comprising synthetic peptide copolymers for preventing graft rejection Compositions and methods for the treatment of graft rejection associated with transplantation of tissues and organs include combined treatment involving at least one agent selected from Copolymer 1, a copolymer 1-related heteropolymer or an ordered peptide in combination with at least one additional known immunosuppressive agent. Compositions and methods for ... 12/07/06 - 20060276389 - Fugetactic proteins, compositions and methods of use This invention relates to compositions and methods that modulate the movement of cells with migratory capacity. More specifically, the invention relates to compositions and methods for promoting migratory movement, fugetaxis, of cells from a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions ... 12/07/06 - 20060276388 - Hip/pap polypeptide compositions for use in liver regeneration and for the prevention of liver failure This invention is based on the experimental finding that HIP/PAP has mitogenic and antiapoptotic effects in vitro on hepatocytes in primary culture. Moreover, HIP/PAP is a mitogenic and anti-apoptotic molecule for hepatocytes, in vivo, during liver failure and liver regeneration. The present invention is also based on the experimental finding ... 12/07/06 - 20060276387 - Method of controlling transcription insulin gene A method for promoting insulin gene transcription, which comprises the step of inhibiting binding of IPF1 and any one of proteins selected from the following group: (i) HNF3G, (ii) PHF1, and (iii) DLX4; and a method for screening a substance that promotes insulin gene transcription, which comprises the step of ... 12/07/06 - 20060276386 - Use of substances inhibiting the association of said protein with ubiquitin c-terminal hydrolase for altering cellular responses to tgf-beta or bmp Disclosed is a pharmaceutical composition for altering cellular responses to TGFβs and/or BMPs; the composition comprising a molecule which prevents, inhibits or reduces the association of a Smad protein with a UCH, in admixture with a physiologically acceptable carrier, excipient or diluent. ... 12/07/06 - 20060276385 - Anti-inflammatory agents and methods of their use The present disclosure provides compositions and methods for reducing or inhibiting vascular inflammation, for example inflammation resulting from unstable blood flow conditions such as oscillatory shear. Representative compositions include an antagonist of BMPs, for example BMP4, or BMP receptors, for example BMPR-I and/or BMPR-II, in an amount sufficient to for ... 12/07/06 - 20060276384 - Peptides and medicinal compositions containing the same This invention provides a pharmaceutical composition comprising, as an active ingredient, a peptide derived from a PACAP or VIP peptide or a pharmaceutically acceptable salt thereof. This invention provides a PACAP/VIP derivative that can inhibit tautomerization in a solution and that can be applied to clinical applications over a long ... 12/07/06 - 20060276383 - Full length polynucleotide coding chicken type ii collagen and the use of it The present invention relates to a nucleic acid molecule as set forth in SEQ ID NO:1 comprising a polynucleotide sequence encoding full length chicken type II collagen (CCII), or a fragment thereof in possession of the same biological functions as well as CCII encoded thereof. It also relates to a ... 12/07/06 - 20060276382 - Materials and methods for treatment of allergic diseases The present invention pertains to a method for treatment of allergic diseases by administering a natriuretic hormone peptide (NHP), or a nucleic acid sequence encoding NHP, to a patient in need thereof. In another aspect, the present invention concerns an expression vector comprising a nucleic acid sequence encoding NHP. In ... 12/07/06 - 20060276381 - Remedy for diabetes The invention relates to a prophylactic or therapeutic for diabetes mellitus which comprises a growth-hormone secretagogue receptor (GHS-R) antagonist as an active ingredient, as well as a method of lowering the blood glucose level by administering a GHS-R antagonist. The invention further relates to a prophylactic or therapeutic which comprises ... 11/30/06 - 20060270604 - Pharmaceutical preparations of fn3 polypeptides for human treatments Disclosed herein are proteins that include an immunoglobulin fold and that can be used as scaffolds. Also disclosed herein are nucleic acids encoding such proteins and the use of such proteins in diagnostic methods and in methods for evolving novel compound-binding species and their ligands. ... 11/30/06 - 20060270603 - Amidated parathyroid hormone fragments and uses thereof C-terminal amidated human parathyroid hormone analogs PTH 1-32-NH2 and PTH 1-33-NH2 are biologically active and can be used for the treatment of various bone related diseases and conditions. ... 11/30/06 - 20060270602 - Mutants of bone morphogenetic proteins The present invention relates to novel mutants of bone morphogenetic proteins (BMPs) useful as inhibitors of heterotopic ossification. Specifically, the present invention relates to novel mutants containing only the entire region involved in the formation of finger 2 including the wrist epitope of a BMP with a specific cysteine residue ... 11/30/06 - 20060270601 - Arts c-terminus fragments and mimetics thereof This invention provides isolated peptides comprising a C-terminal fragment of an ARTS protein, isolated nucleotides encoding same, mimetics and small molecule analogues of same, and therapeutic applications comprising administering a peptide, nucleic acid, or mimetic compound of the present invention. This invention also provides isolated complexes comprising a C-terminal fragment ... 11/30/06 - 20060270600 - Anti-cancer agents An anti-cancer agent comprising as an active component a protein which is a diphtheria toxin mutant such as CRM197, has an activity to inhibit binding of HB-EGF to an EGR receptor and substantially does not have toxicity of diphtheria toxin. The anti-cancer agent is particularly effective for the treatment of ... 11/30/06 - 20060270599 - Inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity A proteinaceous molecule comprising a lysine and/or arginine residue and/or a functional equivalent thereof, capable of providing enhanced levels of plasmin in a mammal through tPA-mediated plasminogen activation for use as a pharmaceutical. Methods of treating diseases associated with angiogenesis and/or inflammatory disorders and/or conformational disorders and/or aging. Also, a ... 11/30/06 - 20060270598 - Method of treatment using adiponectin variants A method of treating a mammal with an adiponectin mediated disorder comprising administering a therapeutically effective amount of an adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin ... 11/30/06 - 20060270597 - Compositions of thap-family chemokine binding domains Among the compositions and methods described herein are compositions comprising THAP-family chemokine binding domains as well as fragments and homologs thereof. Also disclosed are compositions comprising THAP-family chemokine binding domains as well as fragments and homologs thereof fused to various molecules. ... 11/30/06 - 20060270596 - Compositions of thap-family chemokine binding domains Among the compositions and methods described herein are compositions comprising THAP-family chemokine binding domains as well as fragments and homologs thereof. Also disclosed are compositions comprising THAP-family chemokine binding domains as well as fragments and homologs thereof fused to various molecules. ... 11/30/06 - 20060270595 - Nucleic acids encoding compositions of thap-family chemokine binding domains Among the compositions and methods described herein are nucleic acids encoding compositions comprising THAP-family chemokine binding domains as well as fragments and homologs thereof. Also disclosed are nucleic acids encoding compositions comprising THAP-family chemokine binding domains as well as fragments and homologs thereof fused to various molecules. Also disclosed are ... 11/30/06 - 20060270594 - Methods and compositions for modulating hyperstabilized c-met The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by inhibiting a hyperstabilized c-met protein. ... 11/30/06 - 20060270593 - Novel molecules of the pyrin/nbs/lrr protein family and uses thereof Novel PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 proteins, the invention further provides PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 fusion proteins, antigenic peptides and ... 11/30/06 - 20060270592 - Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions The invention further features novel methods and compositions for treating and preventing dry eye by administration of neurotransmitters and/or neuropeptides, optionally in formulation with various other agents, as well as kits for the use of such novel formulations and methods. ... 11/30/06 - 20060270591 - Androgen receptor coregulators Disclosed are compositions and methods related to androgen receptor coregulators. ... 11/23/06 - 20060264377 - |